Innovative Cellular Therapeutics, a clinical-stage biotechnology company developing a robust platform for liquid and solid tumor chimeric antigen receptor T cell therapies, today announced the addition of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing.
At Rocket Pharmaceuticals and WuXi AppTec, Dr. Ballas previously served in senior engineering positions with an emphasis on gene and cell-based therapies. “Chris is a valuable addition to the ICT management team as it will lead our production efforts and expand our related infrastructure,” added Dr. Xiao.
Dr. Ballas has over 20 years of cell and gene therapy expertise. Until recently, he served as Marketing Vice President for Rocket Pharmaceuticals, a major U.S. gene therapy firm traded publicly.
He previously served as Senior Director of Process Development and Marketing for WuXi AppTec, where he was responsible for gene therapy clients ‘ manufacturing operations and program management.
Dr. Ballas supervised main projects such as stem cell therapy CAR-T, TIL, and classic CD34. Dr. Ballas performed clinical trials of autologous cell therapy for Cook Medical prior to WuXi AppTec.
As a faculty member, Dr. Ballas developed his own research programs targeting stem cells for gene therapy, resulting in a collaborative development with colleagues at the University of California Riverside of an ultra-high-performance microinjection device.
In the past, Dr. Ballas has worked as an independent consultant for several gene therapy firms and the development and use of viral vectors for gene therapy with contributions to chemistry, design and regulation, legal filings, and regulatory meetings.
Dr. Ballas has a Ph.D. in Cellular and Molecular Pathology from the Vanderbilt University School of Medicine and was a Children’s Brittle Bone Foundation fellow at the Case Western Reserve University School of Medicine during his post-doctoral internship.
Dr. Ballas said, “I am passionate about solving the practical challenges of producing and using viral vectors to deliver genes and create differentiated therapies. ICT’s CAR-T platform is unique and compelling, and I look forward to leveraging my experience to optimize and expand our manufacturing capability to produce world-class products capable of transforming immune cancer.